JP2017500017A - 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 - Google Patents

生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Download PDF

Info

Publication number
JP2017500017A
JP2017500017A JP2016532136A JP2016532136A JP2017500017A JP 2017500017 A JP2017500017 A JP 2017500017A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A JP2017500017 A JP 2017500017A
Authority
JP
Japan
Prior art keywords
culture
cells
cell
liters
cumulative amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016532136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500017A5 (OSRAM
Inventor
ウィリアム シー． ヤン，
ウィリアム シー． ヤン，
ジウイー ル，
ジウイー ル，
ヤオ−ミン フアン，
ヤオ−ミン フアン，
ハン ユアン，
ハン ユアン，
ラシュミ クシルサガル，
ラシュミ クシルサガル，
トーマス リル，
トーマス リル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2017500017A publication Critical patent/JP2017500017A/ja
Publication of JP2017500017A5 publication Critical patent/JP2017500017A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016532136A 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 Withdrawn JP2017500017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919629P 2013-12-20 2013-12-20
US61/919,629 2013-12-20
PCT/US2014/071701 WO2015095809A1 (en) 2013-12-20 2014-12-19 Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000268A Division JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Publications (2)

Publication Number Publication Date
JP2017500017A true JP2017500017A (ja) 2017-01-05
JP2017500017A5 JP2017500017A5 (OSRAM) 2018-02-08

Family

ID=52347449

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016532136A Withdrawn JP2017500017A (ja) 2013-12-20 2014-12-19 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020000268A Withdrawn JP2020054388A (ja) 2013-12-20 2020-01-06 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
JP2022197095A Pending JP2023022317A (ja) 2013-12-20 2022-12-09 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用

Country Status (4)

Country Link
US (2) US20160289633A1 (OSRAM)
EP (1) EP3083933A1 (OSRAM)
JP (3) JP2017500017A (OSRAM)
WO (1) WO2015095809A1 (OSRAM)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
CA3000926A1 (en) * 2015-11-02 2017-05-11 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins in perfusion mode
CN116083344A (zh) 2016-01-26 2023-05-09 勃林格殷格翰国际公司 对连续流动搅拌釜反应器细胞培养系统的连接灌注
CN115044471B (zh) 2016-08-27 2025-05-27 三维生物科技有限公司 生物反应器
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
ES2919850T3 (es) 2017-10-16 2022-07-28 Regeneron Pharma Procedimientos de perfusión
US20200323958A1 (en) * 2017-11-13 2020-10-15 Amgen Inc. Methods for producing protein products
CN111315780A (zh) * 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺
US12365865B2 (en) * 2018-04-29 2025-07-22 Regenxbio Inc. Scalable clarification process for recombinant AAV production
US12071607B2 (en) 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20210403971A1 (en) * 2018-11-02 2021-12-30 Kyowa Kirin Co., Ltd. Method for preparing liquid medium
EP3914696A4 (en) * 2019-01-25 2022-12-14 Biogen MA Inc. SEED CULTIVATION METHOD FOR THE PRODUCTION OF AAV
CN114514311A (zh) * 2019-08-01 2022-05-17 百时美施贵宝公司 改进补料分批细胞培养物中蛋白质产量的方法
MX2023012903A (es) 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
JP2025509328A (ja) * 2022-03-07 2025-04-11 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 改良されたバッチａａｖ産生システムおよび方法
CA3266232A1 (en) * 2022-09-06 2024-03-14 Amgen Inc. CELL CULTURE METHODS UNDER LOW PERFUSION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
DE60124780T2 (de) * 2000-12-20 2007-10-11 Bayer Pharmaceuticals Corp., West Haven Vorrichtung und verfahren zur serienvermehrung von säugerzellen zum animpfen
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
AU2003211602B2 (en) 2002-02-21 2008-05-22 Tokyo Gas Company Limited Diagnostic reagent for evaluation of pharmacological effect of medicine, and method and reagent for screening pharmaceutical agents comprising enzyme, enzyme inhibitor or receptor ligand and/or prodrugs thereof for one having high medicative efficacy and/or small side effect
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1720972B1 (en) * 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CA2842964A1 (en) * 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
KR20110005862A (ko) 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
EP2268807A2 (en) 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
JP2011518790A (ja) * 2008-04-23 2011-06-30 シムフォゲン・アクティーゼルスカブ ポリクローナルタンパク質を製造する方法
EP2331678B1 (en) * 2008-06-13 2015-09-30 Janssen Biotech, Inc. Methods for obtaining high viable cell density in mammalian cell culture
AU2010325787B2 (en) 2009-12-06 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
AU2011207425A1 (en) * 2010-01-25 2012-08-16 Ventria Bioscience Methods and compositions for improving protein production
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103415610B (zh) 2011-03-18 2016-10-19 通用电气健康护理生物科学股份公司 用于培养细胞的弹性袋
JP5897708B2 (ja) 2011-07-01 2016-03-30 アムジエン・インコーポレーテツド 哺乳類細胞培養物
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PADAWER ISHAI ET AL.: "Case Study: An accelerated 8-day monoclonal antibody production process based on high seeding densit", BIOTECHNOLOGY PROGRESS, vol. 29, no. 3, JPN6018041861, 18 April 2013 (2013-04-18), pages 829 - 832, ISSN: 0004230568 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378517B2 (en) 2014-06-06 2025-08-05 Genzyme Corporation Perfusion culturing methods and uses thereof
JP2017521057A (ja) * 2014-06-09 2017-08-03 ジェンザイム・コーポレーション シードトレイン法およびその使用
JP2020533983A (ja) * 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
JP2021516971A (ja) * 2018-03-09 2021-07-15 嘉和生物▲薬▼▲業▼有限公司 上流生産プロセスでの段階的な分画による生体高分子の生産方法、生産モジュール、および生産における使用
JP2022527582A (ja) * 2019-04-11 2022-06-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP7684224B2 (ja) 2019-04-11 2025-05-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ケト酸を含む細胞培養培地
JP2022540920A (ja) * 2019-07-16 2022-09-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP7680418B2 (ja) 2019-07-16 2025-05-20 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 高密度連続接種の細胞培養方法及びその応用
JP2023553117A (ja) * 2020-12-08 2023-12-20 パートナー セラピューティクス インコーポレイテッド 顆粒球マクロファージコロニー刺激因子の製造

Also Published As

Publication number Publication date
WO2015095809A1 (en) 2015-06-25
US20160289633A1 (en) 2016-10-06
JP2023022317A (ja) 2023-02-14
JP2020054388A (ja) 2020-04-09
EP3083933A1 (en) 2016-10-26
US20250382568A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
US20250382568A1 (en) Use of perfusion seed cultures to improve biopharmaceutical fedbatch production capacity and product quality
US20230117598A1 (en) Mammalian cell culture
KR101540124B1 (ko) 항노화 화합물을 사용하는 단백질의 생산 방법
KR102604988B1 (ko) 관류 배지
KR102604992B1 (ko) 관류 배지
US10676772B2 (en) Control of protein glycosylation by culture medium supplementation and cell culture process parameters
JP2024050574A (ja) 哺乳動物細胞培養物によって生産されるニューブラスチン抗体
US20150353883A1 (en) Medium Supplements for Improved Process Performance
JP7495483B2 (ja) 濃縮灌流培地
US12441980B2 (en) Methods for overcoming glutamine deprivation during mammalian cell culture
US10717965B2 (en) Mammalian cell culture-produced neublastin antibodies
JP2021503916A (ja) 哺乳動物細胞の培養方法
US20170029859A1 (en) Medium supplements for improved process performance
US20170327786A1 (en) Hypotaurine, GABA, Beta-Alanine, and Choline for Control of Waste Byproduct Accumulation in Mammalian Cell Culture Process
HK1142095B (en) Methods of protein production using anti-senescence compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190322

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200114

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200313

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200319